These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Synthesis and evaluation of heparin immobilized "side-on" to polystyrene microspheres coated with end-group activated polyethylene oxide. Joshi P; Schilke KF; Fry A; McGuire J; Bird K Int J Biol Macromol; 2010 Aug; 47(2):98-103. PubMed ID: 20621768 [TBL] [Abstract][Full Text] [Related]
6. Sugars slide into heparin activity. Sinaÿ P Nature; 1999 Apr; 398(6726):377-8. PubMed ID: 10201366 [No Abstract] [Full Text] [Related]
7. Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Peterson S; Frick A; Liu J Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498 [TBL] [Abstract][Full Text] [Related]
8. Study on syntheses and anticoagulant action of heparin/rare earth nano-oxides hybrid material. Wang KJ; Li HX; Song YM; Luan NN; Xian P Biopolymers; 2010 Oct; 93(10):887-92. PubMed ID: 20564053 [TBL] [Abstract][Full Text] [Related]
11. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure. Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930 [TBL] [Abstract][Full Text] [Related]
12. The synthesis of 1,2-cis-amino containing oligosaccharides toward biological investigation. Manabe S Methods Enzymol; 2010; 478():413-35. PubMed ID: 20816492 [TBL] [Abstract][Full Text] [Related]
13. Recent innovations in the structural analysis of heparin. Yates EA; Rudd TR Int J Cardiol; 2016 Jun; 212 Suppl 1():S5-9. PubMed ID: 27264867 [TBL] [Abstract][Full Text] [Related]
14. Heparin and low molecular weight heparin in thrombosis and beyond. Mousa SA Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642 [TBL] [Abstract][Full Text] [Related]
16. [Low molecular weight heparin in venous thromboembolism. Mechanism of action, therapy and prophylaxis]. Stammler F; Diehm C Dtsch Med Wochenschr; 1998 May; 123(19):604-11. PubMed ID: 9618643 [No Abstract] [Full Text] [Related]
17. [Cardiovascular system drugs. 10/12. The heparins]. Nerich V; Limat S; Woronoff-Lemsi MC Soins; 2005 Mar; (693):51-3. PubMed ID: 15796485 [No Abstract] [Full Text] [Related]
18. Programmable One-Pot Synthesis of Heparin Pentasaccharide Fondaparinux. Dey S; Lo HJ; Wong CH Org Lett; 2020 Jun; 22(12):4638-4642. PubMed ID: 32496799 [TBL] [Abstract][Full Text] [Related]
19. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Wygrecka M; Jablonska E; Guenther A; Preissner KT; Markart P Thromb Haemost; 2008 Mar; 99(3):494-501. PubMed ID: 18327397 [TBL] [Abstract][Full Text] [Related]
20. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Fareed J; Callas D; Hoppensteadt DA; Lewis BE; Bick RL; Walenga JM Semin Hematol; 1999 Jan; 36(1 Suppl 1):42-56. PubMed ID: 9930564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]